<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Solstice Oncology</title>
    <link>https://www.biospace.com/employer/3076358/solstice-oncology</link>
    <description>Solstice Oncology</description>
    <language>en-US</language>
    <lastBuildDate>Fri, 24 Jul 2026 13:09:20 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076358/solstice-oncology.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth</title>
      <link>https://www.biospace.com/press-releases/harbour-biomed-announces-positive-profit-alert-for-2026-interim-results-marking-seventh-consecutive-profitable-half-year-as-platform-based-advantages-drive-sustainable-growth</link>
      <description />
      <pubDate>Fri, 24 Jul 2026 13:09:20 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/harbour-biomed-announces-positive-profit-alert-for-2026-interim-results-marking-seventh-consecutive-profitable-half-year-as-platform-based-advantages-drive-sustainable-growth</guid>
    </item>
    <item>
      <title>Solstice rises with $225M to develop next-gen CTLA-4 drug from China</title>
      <link>https://www.biospace.com/business/solstice-rises-with-225m-to-develop-next-gen-ctla-4-drug-from-china</link>
      <dc:creator>Annalee Armstrong</dc:creator>
      <description>Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from China’s Harbour BioMed.</description>
      <pubDate>Wed, 09 Sep 2026 11:01:00 GMT</pubDate>
      <guid>https://www.biospace.com/business/solstice-rises-with-225m-to-develop-next-gen-ctla-4-drug-from-china</guid>
    </item>
    <item>
      <title>Solstice Oncology Launches with $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy</title>
      <link>https://www.biospace.com/press-releases/solstice-oncology-launches-with-225-million-series-a-financing-to-advance-porustobart-a-neoadjuvant-immuno-oncology-therapy</link>
      <description />
      <pubDate>Wed, 09 Sep 2026 11:57:32 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/solstice-oncology-launches-with-225-million-series-a-financing-to-advance-porustobart-a-neoadjuvant-immuno-oncology-therapy</guid>
    </item>
    <item>
      <title>Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy</title>
      <link>https://www.biospace.com/press-releases/harbour-biomed-partner-solstice-oncology-announces-225-million-series-a-financing-to-advance-porustobart-a-neoadjuvant-immuno-oncology-therapy</link>
      <description />
      <pubDate>Wed, 09 Sep 2026 12:14:33 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/harbour-biomed-partner-solstice-oncology-announces-225-million-series-a-financing-to-advance-porustobart-a-neoadjuvant-immuno-oncology-therapy</guid>
    </item>
    <item>
      <title>5 biggest venture capital raises of Q3 2026</title>
      <link>https://www.biospace.com/business/5-biggest-venture-capital-raises-of-q3-2026</link>
      <dc:creator>Tristan Manalac</dc:creator>
      <description>Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked assets, as well as AI-driven drugmakers.</description>
      <pubDate>Wed, 07 Oct 2026 04:06:00 GMT</pubDate>
      <guid>https://www.biospace.com/business/5-biggest-venture-capital-raises-of-q3-2026</guid>
    </item>
  </channel>
</rss>
